48
Participants
Start Date
December 31, 2010
Primary Completion Date
July 31, 2015
Study Completion Date
January 31, 2017
Amgen 386
"For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.~For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.~For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week."
Bevacizumab
The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.
New York - Presbyterian/Columbia University Medical Center, New York
University of Virginia, Charlottesville
University of California Los Angeles, Los Angeles
Massachusetts General Hosptial, Boston
Dana-Farber Cancer Institute, Boston
University of Massachusetts, Worcester, Worcester
Collaborators (1)
Amgen
INDUSTRY
Dana-Farber Cancer Institute
OTHER